Skip To Main Content
Andrew Bomback on Muck Rack

Andrew Bomback

As seen in: Nature, CBC News, The Atlantic, The MIT Press, The Daily Beast, Medscape, HCP Live, Library Journal, McSweeney's, The Millions and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Andrew

Contact Andrew, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Phase 3 VALIANT Results for Pegcetacoplan In C3G, IC-MPGN, With Andrew Bomback, MD

|
By Andrew Bomback
| consultantlive.com
Positive phase 3 VALIANT results showed pegcetacoplan reduced proteinuria by 68% and stabilized kidney function in adult and adolescent patients with C3 glomerulopathy (C3G) and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN).1 The findings also reported evidence of C3 deposit clearance, including in patients with post-transplant recurrent C3G, highlighting pegcetacoplan’s potential to directly target pathogenic complement activity.1 Pegcetacoplan is a...
Open in Who Shared View Duplicates (2) Issue with article?

Advances in Glomerular Diseases From ASN 2025

|
By Andrew Bomback
| Medscape Verified
Advances in glomerular diseases (GDs), as presented at the American Society of Nephrology (ASN) 2025 annual meeting, include updated results on pegcetacoplan, emerging targeted therapies, and data indicating GD outcomes across the lifespan, as reported by Dr Andrew Bomback of Columbia University in New York. Dr Bomback begins with 52-week data from the phase 3 VALIANT trial.
Open in Who Shared Issue with article?

Treating the Whole Patient: Addressing the Broader Unmet Needs in C3G Management

|
By Sayna Norouzi, Jonathan Barratt, Andrew Bomback, Bradley P Dixon, Brendon L Neuen
| consultantlive.com
Advancing Treatment for C3G; Targeting the Complement System for Personalized Kidney Care - Episode 18 Published on: , , , , Panelists discuss how the complexity of diagnosing C3 glomerulopathy (C3G), the need for long-term treatment options, and the importance of addressing unmet needs, including the psychological impact on patients and families, highlights the challenges and future directions in improving care for these individuals.
Open in Who Shared View Duplicates (2) Issue with article?
See all 53 licensed articles (73 Total)